Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2026-03-23 Major Shareholding Noti…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 94% confidence The document is a ‘주식등의 대량보유상황보고서(일반)’ filed under the Capital Markets Act, detailing the number of shares held, changes in holdings, major contracts and relationships, and the purpose of acquisition by a major shareholder (Vivozon Holdings and its special relations). This corresponds directly to a Major Shareholding Notification (crossing reporting thresholds and large block holdings).
2026-03-23 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Vivozon Pharmaceutical, covering the fiscal year 2025 (2025.01.01-2025.12.31). It contains detailed company information, history, capital structure, and business operations, which are characteristic of an Annual Report (10-K equivalent in the Korean regulatory context). FY 2025
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 96% confidence The document is titled “감사보고서 제출” (Audit Report Submission) and contains detailed auditor opinions on consolidated and separate financial statements, key financial metrics, auditor name, and audit report reception date. It does not present a full annual report or earnings highlights, but rather the standalone audit report. This fits the definition of an Audit Report / Information submission. FY 2025
2026-03-23 Korean
주주총회소집공고
AGM Information Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Vivozon Pharmaceutical. It contains the agenda for the Annual General Meeting (AGM), including reports on financial statements, director appointments, and remuneration limits. While it includes financial data (financial statements), this is provided as part of the 'Management Reference' (경영참고사항) required for the AGM notice to shareholders. Since the primary purpose of the document is to formally convene the AGM and provide the necessary materials for shareholders to vote, it is classified as AGM Information.
2026-03-16 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Vivozon Pharmaceutical. It details the date, location, agenda items (such as financial statement approval, director/auditor appointments, and remuneration limits), and provides biographical details for the nominees. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2026-03-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose changes in their shareholdings. According to the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2026-03-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.